Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$2.00 USD
-0.02 (-0.99%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.99 -0.01 (-0.50%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TARA 2.00 -0.02(-0.99%)
Will TARA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARA
Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now
TARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TARA
Veeva: Fiscal Q2 Earnings Snapshot
Protara Therapeutics price target lowered by $5 at Oppenheimer, here's why
H.C. Wainwright Sticks to Its Buy Rating for Protara Therapeutics (TARA)
Protara Therapeutics price target lowered by $2 at Guggenheim, here's why
TARA Stock Earnings: Protara Therapeutics Beats EPS for Q2 2024